Bioreactor scale-up is a critical step in the production of biologics such as therapeutic proteins, monoclonal antibodies (mAbs), and vaccines. Scaling up requires choosing the optimal media formulations, securing reliable supply chains, and maintaining product quality, all while remaining cost-effective. This article outlines five top media-related factors to consider to help you achieve success.
This content is sponsored by:
